We leveraged genotypic and phenotypic information from 41,176 participants from 11 studies that are part of the Psychiatric Genomics Consortium Substance Use Disorder working group (PGC-SUD) to investigate genetic differences between OD cases (n=4,503), OE controls (n=4,173), and opioid-unexposed (OU) controls (n=32,500) using GWAS and polygenic risk score (PRS) analyses. In addition to identifying loci related to OD and OE, we also examined whether OD and OE could be differentiated with respect to their relationship with genetic liability to risk-taking behaviors and negative personality features (i.e., neuroticism), to provide further insights into the genetic architecture underlying opioid use and misuse.
